TCRR News and Press, TCR2 Therapeutics Inc. From 09/28/22

- Completed Phase 1 clinical trial establishes gavo-cel monotherapy as the first anti-mesothelin cell therapy to demonstrate tolerability and clinical benefit - Second RECIST partial response in ovarian cancer supports broad potential of gavo-cel - Consistent tumor regression in 28 of 3...

CAMBRIDGE, Mass., Sept. 27, 2022 (GLOBE NEWSWIRE) -- TCR 2 Therapeutics Inc. (Nasdaq: TCRR), a clinical-stage cell therapy company with a pipeline of novel T cell therapies for patients suffering from solid tumors, today announced that the Company plans to discuss the complete Phase 1 p...

CAMBRIDGE, Mass., Sept. 26, 2022 (GLOBE NEWSWIRE) -- TCR 2 Therapeutics Inc. (Nasdaq: TCRR), a clinical-stage cell therapy company with a pipeline of novel T cell therapies for patients suffering from solid tumors, today announced that management will participate in a fireside chat at t...

CAMBRIDGE, Mass., Sept. 01, 2022 (GLOBE NEWSWIRE) -- Therapeutics Inc. (Nasdaq: TCRR), a clinical-stage cell therapy company with a pipeline of novel T cell therapies for patients suffering from solid tumors, today announced the Compensation Committee of the Board of Directors of TCR 2 ...

TCR² Therapeutics is a company developing two lead oncology drug candidates targeting mesothelin, a protein expressed on different tumors. Its lead candidate gavo-cel, or TC-210, has presented strong data so far in different solid tumors, including tumor regression in 94% of eval...

TCR2 Therapeutics press release ( NASDAQ: TCRR ): Q2 GAAP EPS of -$0.82 misses by $0.02 . TCR 2 ended the second quarter of 2022 with $206.2 million in cash, cash equivalents, and investments compared to $265.6 million as of December 31, 2021. For further det...

- gavo-cel Phase 1 trial dataset anticipated in September 2022 - Initial TC-510 Phase 1 data anticipated in 2H 2022 - Expansion of manufacturing capacity and commencement of gavo-cel clinical trial material production at ElevateBio BaseCamp CAMBRIDGE, Mass., Aug. 08, 2022 (GLOBE NEW...

TCR2 Therapeutics (NASDAQ:TCRR) has appointed Eric Sullivan as Chief Financial Officer. Mr. Sullivan brings nearly 20 years of finance and operations experience in the biotechnology industry working on financial management, strategic planning, and fundraising and capital market transacti...

CAMBRIDGE, Mass., June 27, 2022 (GLOBE NEWSWIRE) -- TCR 2 Therapeutics Inc. (Nasdaq: TCRR), a clinical-stage cell therapy company with a pipeline of novel T cell therapies for patients suffering from solid tumors, today announced the appointment of Eric Sullivan as Chief Financial Offic...

TCR2 Therapeutics press release (NASDAQ:TCRR): Q1 GAAP EPS of -$0.76 misses by $0.01. “We are very pleased with the momentum generated in the last quarter as we initiated the next phases on two clinical programs and expect to present in July an expanded dataset on 30 patients treated w...